Skip to main content
Category

Treatments

EGFR Resister Logo
EGFR Resisters Announcements/UpdatesResearchTreatments

Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY

*March 2025* Abstract Introduction The treatment landscape for people diagnosed with EGFR-mutated (EGFR-m) NSCLC has rapidly evolved, yet there remains limited self-reported information about the lived experience. In this paper, we describe the clinical characteristics and treatment experiences of people living with EGFR-m lung cancer from Project PRIORITY, a patient-driven…
2024 Research Summit Newsletter
EGFR Resisters Announcements/UpdatesResearchTreatments

2024 EGFR Resisters 6th Annual Research Summit Newsletter

*February 2025* The EGFR Resisters Research Summit is an annual event focusing on the advancement of EGFRm treatment paradigms through meaningful collaboration between physician scientist investigators and patients. This special newsletter includes a summit recap and covers its agenda, including the Awardees and their research projects: Dr. Catherine Meador, Detecting Small Cell Transformation in…
Onc Live
ResearchTreatments

REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point

*January 2025* Key Takeaways Zipalertinib demonstrated a 40% ORR and 90% DCR in NSCLC patients with EGFR exon 20 insertion mutations, meeting the trial's primary endpoint. Patients previously treated with amivantamab showed a higher ORR of 50%, indicating potential efficacy in this subgroup. Common treatment-related adverse effects included rash, paronychia,…
ResearchTreatments

Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study

*January 2025* Abstract Introduction Amivantamab, an EGFR-MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced NSCLC as monotherapy or combined with other agents. Intravenous amivantamab is associated with a 67% infusion-related reaction (IRR) rate. Methods The phase 2 SKIPPirr study (NCT05663866) enrolled participants with EGFR-mutated (exon 19 deletion…